US 11,793,855 B2
TFPI inhibitors and methods of use
Michael Dockal, Vienna (AT); Rudolf Hartmann, Bisamberg (AT); Markus Fries, Vienna (AT); Friedrich Scheiflinger, Vienna (AT); Hartmut Ehrlich, Paris (FR); Ulrich Reineke, Berlin (DE); Frank Osterkamp, Berlin (DE); and Thomas Polakowski, Berlin (DE)
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Filed by TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka (JP)
Filed on Jan. 14, 2019, as Appl. No. 16/246,987.
Application 16/246,987 is a division of application No. 15/373,742, filed on Dec. 9, 2016, granted, now 10,201,586.
Application 13/846,359 is a division of application No. 13/026,070, filed on Feb. 11, 2011, granted, now 8,450,275, issued on May 28, 2013.
Application 15/373,742 is a continuation of application No. 14/677,581, filed on Apr. 2, 2015, granted, now 9,556,230, issued on Jan. 31, 2017.
Application 14/677,581 is a continuation of application No. 13/846,359, filed on Mar. 18, 2013, granted, now 9,018,167, issued on Apr. 28, 2015.
Claims priority of provisional application 61/315,758, filed on Mar. 19, 2010.
Prior Publication US 2019/0134147 A1, May 9, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/10 (2006.01); G16B 15/00 (2019.01); G16B 20/00 (2019.01); C07K 14/81 (2006.01); G01N 33/68 (2006.01); G16B 20/50 (2019.01); G16B 20/30 (2019.01); C07K 14/00 (2006.01); C07K 7/08 (2006.01); C07K 1/14 (2006.01); A61K 38/00 (2006.01)
CPC A61K 38/10 (2013.01) [C07K 1/14 (2013.01); C07K 7/08 (2013.01); C07K 14/00 (2013.01); C07K 14/8114 (2013.01); G01N 33/68 (2013.01); G16B 15/00 (2019.02); G16B 20/00 (2019.02); G16B 20/30 (2019.02); G16B 20/50 (2019.02); A61K 38/00 (2013.01); A61K 2121/00 (2013.01); G01N 2333/745 (2013.01); G01N 2333/8114 (2013.01); G01N 2333/96444 (2013.01); G01N 2333/96447 (2013.01); G01N 2500/02 (2013.01); G01N 2500/04 (2013.01); G01N 2500/20 (2013.01)] 22 Claims
 
1. A method for treating a subject suffering from a blood coagulation disorder, the method comprising administering to the subject a peptide comprising (a) the amino acid sequence having at least 80% identity to SYYKWH[CA-Moo-RDLKGTFTC]VWVKF (SEQ ID NO: 1334) or (b) a variant of SEQ ID NO: 1334, wherein the variant comprises one or two amino acid substitution(s), deletion(s) or insertion(s).